The University of Virginia Comprehensive Cancer Center seeks participants ages 70 and over with Advanced Non-Small Cell Lung Cancer. In this study, you will either get pembrolizumab alone until disease progression, or chemotherapy from study-provided list of allowable choices combined with pembrolizumab for up to 2 years or until disease progression. There is evidence that both immunotherapy and immunotherapy combined with chemotherapy are effective at stabilizing your type of cancer compared to chemotherapy alone.
It is not possible to know now if the study approach using immunotherapy alone will have positive effects with fewer side effects compared to the combination. There is a risk that the study approach with immunotherapy alone may not be as good as the usual approach with immunotherapy combined with chemotherapy at shrinking or stabilizing your cancer. This study may help doctors learn things that can help other people in the future.
If you are enrolled in treatment, you may need to have the following exams, tests, and procedures:
• Blood counts done weekly during the first cycle of treatment.
• Thyroid testing done every 3 months.
• Physical exams done weekly during the first cycle.
After you finish your study treatment, your doctor will continue to follow your condition for 5 years from the date of registration for survival. You will be followed every 3 months < 2 years from registration, and every 6 months for years 2-5.
Additional information found here: https://clinicaltrials.gov/study/NCT06096844
For questions, contact:
uvacancertrials@hscmail.mcc.virginia.edu
No Compensation